Read in the 10-K filed Feb 21, 2025As a global healthcare company, public health crises, such as the widespread outbreaks of infectious diseases, may negatively impact certain Abbott's operations. Health concerns and significant changes in political or economic conditions caused by such outbreaks can cause, and during the COVID-19 pandemic caused, significant reductions in demand for certain products, increased difficulty in serving customers, disruptions to manufacturing and supply chains, and negative effects on certain of Abbott’s operations as well as the operations of its suppliers, distributors and other third-party partners. Furthermore, such widespread outbreaks may impact, and during the COVID-19 pandemic impacted, the broader
Pandemics
210 of 1505 companies dropped a paragraph in Risk Factors that uses one of these words:
pandemic, COVID, epidemic, outbreak.
The paragraph was in the earlier 10-K and nothing like it is in the latest.
It counts text; it does not say how serious a risk is. Words in capitals only (such as AI) must be in capitals.
By sector
Sector is the SEC's industry description of the company. The bar is the share of that sector's companies compared; each count opens that sector's quotes below.
- Apparel & Other Finishd Prods of Fabrics & Similar Matl 2 of 2
- Communications Equipment, NEC 2 of 2
- Broadwoven Fabric Mills, Man Made Fiber & Silk 1 of 1
- Fabricated Plate Work (Boiler Shops) 1 of 1
- Flat Glass 1 of 1
- Hotels, Rooming Houses, Camps & Other Lodging Places 1 of 1
- Investors, NEC 1 of 1
- Land Subdividers & Developers (No Cemeteries) 1 of 1
- Meat Packing Plants 1 of 1
- Real Estate Operators (No Developers) & Lessors 1 of 1
- Retail-Drug Stores and Proprietary Stores 1 of 1
- Retail-Jewelry Stores 1 of 1
- Secondary Smelting & Refining of Nonferrous Metals 1 of 1
- Services-Hospitals 1 of 1
- Services-Motion Picture Theaters 1 of 1
- Services-Nursing & Personal Care Facilities 1 of 1
- Wholesale-Electrical Apparatus & Equipment, Wiring Supplies 1 of 1
- Wholesale-Misc Durable Goods 1 of 1
- Wholesale-Professional & Commercial Equipment & Supplies 1 of 1
- Miscellaneous Chemical Products 2 of 3
- Rubber & Plastics Footwear 2 of 3
- Services-Consumer Credit Reporting, Collection Agencies 2 of 4
- Services-Help Supply Services 2 of 4
- Ship & Boat Building & Repairing 2 of 4
- Adhesives & Sealants 1 of 2
- Cigarettes 1 of 2
- Converted Paper & Paperboard Prods (No Contaners/Boxes) 1 of 2
- Dental Equipment & Supplies 1 of 2
- Gold and Silver Ores 1 of 2
- Household Appliances 1 of 2
- Leather & Leather Products 1 of 2
- Mineral Royalty Traders 1 of 2
- Ophthalmic Goods 1 of 2
- Paper Mills 1 of 2
- Retail-Department Stores 1 of 2
- Retail-Miscellaneous Shopping Goods Stores 1 of 2
- Services-Specialty Outpatient Facilities, NEC 1 of 2
- Special Industry Machinery, NEC 1 of 2
- Telephone & Telegraph Apparatus 1 of 2
- Wholesale-Lumber & Other Construction Materials 1 of 2
- Laboratory Analytical Instruments 3 of 7
- Services-Educational Services 3 of 7
- Other 4 of 10
- Refuse Systems 2 of 5
- Oil & Gas Field Machinery & Equipment 2 of 6
- Printed Circuit Boards 2 of 6
- Services-Computer Programming Services 2 of 6
- Agricultural Chemicals 1 of 3
- Computer & office Equipment 1 of 3
- Computer Communications Equipment 1 of 3
- Computer Peripheral Equipment, NEC 1 of 3
- Engines & Turbines 1 of 3
- Metal Cans 1 of 3
- Services-Membership Sports & Recreation Clubs 1 of 3
- Services-Misc Health & Allied Services, NEC 1 of 3
- Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics 1 of 3
- Sporting & Athletic Goods, NEC 1 of 3
- Telephone Communications (No Radiotelephone) 1 of 3
- Television Broadcasting Stations 1 of 3
- Services-Medical Laboratories 2 of 7
- Finance Services 9 of 34
- Accident & Health Insurance 1 of 4
- Aircraft 1 of 4
- Grain Mill Products 1 of 4
- Pumps & Pumping Equipment 1 of 4
- Real Estate Agents & Managers (For Others) 1 of 4
- Retail-Eating & Drinking Places 1 of 4
- Services-General Medical & Surgical Hospitals, NEC 1 of 4
- Services-Home Health Care Services 1 of 4
- Special Industry Machinery (No Metalworking Machinery) 1 of 4
- Pharmaceutical Preparations 12 of 49
- Services-Computer Programming, Data Processing, Etc. 4 of 18
- Biological Products, (No Diagnostic Substances) 5 of 23
- Semiconductors & Related Devices 8 of 37
- Services-Computer Processing & Data Preparation 3 of 14
- Drilling Oil & Gas Wells 1 of 5
- Industrial Organic Chemicals 1 of 5
- Mining & Quarrying of Nonmetallic Minerals (No Fuels) 1 of 5
- Miscellaneous Fabricated Metal Products 1 of 5
- Perfumes, Cosmetics & Other Toilet Preparations 1 of 5
- Services-Management Consulting Services 1 of 5
- Water Supply 1 of 5
- National Commercial Banks 7 of 38
- Fire, Marine & Casualty Insurance 5 of 30
- Insurance Agents, Brokers & Service 2 of 12
- Air Transportation, Scheduled 1 of 6
- Communications Services, NEC 1 of 6
- Heavy Construction Other Than Bldg Const - Contractors 1 of 6
- Metal Mining 1 of 6
- Miscellaneous Electrical Machinery, Equipment & Supplies 1 of 6
- Pipe Lines (No Natural Gas) 1 of 6
- Search, Detection, Navigation, Guidance, Aeronautical Sys 1 of 6
- Real Estate Investment Trusts 13 of 84
- Investment Advice 4 of 26
- Retail-Eating Places 2 of 13
- Security Brokers, Dealers & Flotation Companies 2 of 14
- Orthopedic, Prosthetic & Surgical Appliances & Supplies 1 of 7
- Personal Credit Institutions 1 of 7
- Trucking (No Local) 1 of 7
- Motor Vehicle Parts & Accessories 2 of 15
- Crude Petroleum & Natural Gas 3 of 23
- Industrial Instruments For Measurement, Display, and Control 1 of 8
- Security & Commodity Brokers, Dealers, Exchanges & Services 1 of 8
- Electric Services 3 of 26
- Operative Builders 1 of 9
- Retail-Variety Stores 1 of 9
- State Commercial Banks 4 of 43
- Surgical & Medical Instruments & Apparatus 2 of 22
- Life Insurance 1 of 11
- Services-Computer Integrated Systems Design 1 of 14
- Hotels & Motels 1 of 15
- Services-Prepackaged Software 5 of 81
- Commodity Contracts Brokers & Dealers 1 of 17
- Services-Business Services, NEC 2 of 37
344 paragraphs · Pharmaceutical Preparations show all sectors
Read in the 10-K filed Feb 13, 2025We may face delays, disruptions or shortages as a result of public health epidemics or pandemics that may affect our ability to initiate and complete preclinical studies and clinical trials or impact our commercialization efforts. We have previously experienced disruptions to certain clinical and research activities at our contract research organizations, or CROs, due to the COVID-19 pandemic. Any future pandemic or public health emergency could result in delays or pauses in site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis due to changes in hospital or university policies, federal, state or local regulations, diversion of hospital resources or other reasons related to a public health emergency. If a pandemic or public health emergency arises in the future, we may face difficulties recruiting or retaining patients in our ongoing clinical trials, and patients enrolled in our clinical trials may be unable
Read in the 10-K filed Feb 13, 2025In the future, we may experience disruptions from a pandemic or public health emergency that could impact our business and operations, including our ability to obtain regulatory approval for and successfully commercialize our approved products, and we may not be able to meet expectations with respect to commercial sales as a result. In addition, we may experience decreased patient demand for our approved products if current or potential patients decide to delay treatment as a result of a pandemic or public health emergency. Business interruptions from pandemics or public health emergencies, including staffing shortages, raw material or other supply chain shortages, production slowdowns and disruptions in delivery systems, may also adversely impact the third parties we or our collaborators rely on in the U.S. and abroad to sufficiently manufacture our approved products and to produce product candidates in quantities we require, which may impair our commercialization efforts, our research and development activities and the potential commercialization of our product candidates.
Read in the 10-K filed Feb 13, 2025Additionally, timely completion of preclinical activities and initiation of planned clinical trials are dependent upon the availability of, for example, preclinical and clinical trial sites, researchers and investigators, patients or healthy volunteer subjects available for recruitment and enrollment, and regulatory agency personnel, which may be adversely affected by global health matters, such as any pandemic or public health emergency. Health regulatory agencies globally may also experience disruptions in their operations as a result of a pandemic or future public health emergency, which could impact review, inspection and approval timelines.
Read in the 10-K filed Feb 13, 2025While the ultimate impact of any pandemic or public health emergency on our business is uncertain, any negative impacts of such pandemic or public health emergency, alone or in combination with others, could exacerbate other risk factors discussed herein. The full extent to which any pandemic or public health emergency, will negatively affect our operations, financial performance, and stock price will depend on future developments that are highly uncertain and cannot be predicted.
Read in the 10-K filed Feb 27, 2025The terms of our EUA for Comirnaty require that we conduct post-observational studies to evaluate the association between the Pfizer-BioNTech COVID-19 Vaccine (Original monovalent), Pfizer-BioNTech COVID-19 Vaccine, Bivalent, and the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula), and a pre-specified list of adverse events of special interest, including myocarditis and pericarditis, along with deaths and hospitalizations, and severe COVID-19. The required study populations include individuals specified in our September 2023 authorization letter (reissued) as well as populations of interest, such as healthcare workers, pregnant women, immunocompromised individuals and subpopulations with specific comorbidities. Additionally, in relation to the FDA approval for Comirnaty, we are required to complete certain post marketing study requirements and commitments through 2024 and beyond.
Read in the 10-K filed Feb 28, 2025Going forward, variants of COVID-19 or other public health incidents, including the actions taken to slow their spread, could have an adverse impact on our financial condition, our supply chains and other operations, our results of operations, consumer demand for our products and our ability to access capital. The magnitude of any such adverse impacts are not determinable, but could be material, depending on: the duration, intensity, and continued spread of the disease; the imposition of business or movement restrictions in various jurisdictions; the ability to develop vaccines and their availability, acceptance and efficacy; the severity and duration of any economic downturn resulting from such pandemic or other public health incidents; the effect of global supply chain and shipping challenges on the Company; the effectiveness of the Company's efforts at mitigation; and other factors, both known and unknown, many of which are likely to be outside our control.
Read in the 10-K filed Feb 5, 2025•impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business;
Read in the 10-K filed May 29, 2025In February 2022, Roivant’s subsidiary GSG and its affiliate Arbutus filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna and an affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19 (the “Moderna Action”). In November 2022, the District Court denied Moderna’s partial motion to dismiss pursuant to 28 U.S.C. § 1498(a) (“§ 1498”). In March 2023, following the submission of a Statement of Interest in the case by the U.S. Government, the court reaffirmed its prior decision and again ruled that the complaint should not be partially dismissed on the basis of § 1498. In February 2024, the court held a claim construction hearing on disputed terms within the claims of the asserted patents. On April 3, 2024, the court provided its claim construction ruling, in which it construed the disputed claim terms and agreed with GSG and Arbutus’ position on most of the disputed claim terms. Fact discovery in the Moderna Action has been completed, and expert discovery is on-going. The court in the Moderna Action has informed the parties that it plans to update the timing for the summary judgment phase and jury trial, previously scheduled for the second or third quarter of calendar year 2025 and September 2025, respectively.
Read in the 10-K filed Feb 28, 2025Our operations are vulnerable to interruption by fire, severe weather conditions, power loss, telecommunications failure, terrorist activity, public health crises and pandemic diseases, and other natural and man-made disasters or events
Read in the 10-K filed Feb 28, 2025The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017 in the U.S. The TCJA contains significant changes to corporate taxation, including reduction of the U.S. corporate tax rate from 35% to 21%, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, limitation of the tax deduction for interest expense, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. On March 27, 2020, President Trump signed into law the “Coronavirus Aid, Relief, and Economic Security Act” or the CARES Act, which included certain changes in tax law intended to stimulate the U.S. economy in light of the COVID-19 outbreak, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters.
Read in the 10-K filed Feb 25, 2025during a pandemic, we may experience delays or disruptions in our preclinical studies, clinical studies, and non-clinical experiments due to unforeseen circumstances, including but not limited to, interruption of key clinical trial activities, such as clinical trial site data monitoring, and interruption of clinical trial subject visits and study procedures.
Read in the 10-K filed Feb 5, 2025The widespread outbreak of an illness or any other communicable disease, or any other public health crisis, and the governmental and societal responses thereto, could adversely affect our business, results of operations and financial condition.
Read in the 10-K filed Feb 5, 2025Widespread outbreaks of disease or other public health crises and responses thereto have in the past and may in the future negatively impact the global economy, disrupt global supply chains and create significant volatility and disruption of financial markets. For example, during the COVID-19 pandemic, we experienced disruptions in countries and regions in which we manufacture our products and conduct our clinical trials, as well as changes in customer stocking and purchasing patterns. In response to the COVID-19 pandemic, we temporarily closed certain of our facilities and faced other protectionist measures and restrictions imposed by government, which caused certain delays and disruptions in our materials, supply, and which also resulted in delays in our clinical trials due to slowdowns in recruitment for studies and suspended regulatory inspections, delays in regulatory approvals of new products due to reduced capacity or re-prioritization of regulatory agencies and delays in pre-commercial launch activities. The new working environment that emerged as a result of the COVID-19 pandemic, with many employees working remotely, also increased the exposure of many companies, including us, to cyber-attacks and data security breaches. Future outbreaks of disease, including a resurgence of COVID-19, and any government response thereto, could have a material adverse impact on the global economy, our supply chain, our business operations, and our financial performance.
Read in the 10-K filed Feb 26, 2025In addition, our CROs may need to make certain adjustments to the operation of our trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA on March 18, 2020 and generally, and may need to make further adjustments in the future. Many of these adjustments are new and untested, may not be effective, and may have unforeseen effects on the enrollment, progress and completion of these trials and the findings from these trials.